BlossomHill Therapeutics Inc.
BLSM | NASDAQ
$26.80
+$1.06 (+4.12%)
At close: Sep 21, 2026, 4:00 PM ET
$26.14
-$0.66 (-2.46%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Company Profile
Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded in June 2020 and is headquartered in San Diego, CA.
Key Executives
| Name | Position |
|---|---|
| Jingrong Jean Cui | Scientific Founder, President, CEO & Director |
| Antonio Garrido-Montalban | Senior Vice President of Drug Substance |
| Ashley Preston | Senior VP and Head of Regulatory Affairs & Quality Assurance |
| Diane Wang | Senior Vice President of Clinical Pharmacology & Preclinical Development |
| Eugene Y. Rui | Senior Vice President of Chemistry |
| Geoff Oxnard | Chief Medical Officer & Executive VP |
| Jason A. Keyes | CFO & Executive VP |
| Li Yishan | Co-Founder & Executive Chairman |
| Vincent Liptak | General Counsel & Executive VP |
| Yishan Li | Co-Founder & Executive Chairman |
| Z. Jesse Shao | Senior Vice President of CMC |
| Zachary F. Zimmerman | Senior Vice President of Clinical Development |
BlossomHill Therapeutics Inc.
| Country | United States |
| IPO Date | Aug 6, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 63 |
| CEO | Jing Rong Jean Cui |
Contact Details
10255 Science Center Drive, Suite 200 San Diego,
California 92121 United States
Stock Details
| Ticker Symbol | BLSM |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001839970 |
| CUSIP Number | 095130100 |
| ISIN Number | US0951301003 |
| SIC Code | n/a |
Add to Watchlist
Select watchlists to add or remove BLSM